1.4500 -0.04 (-2.68%)
After hours: 7:38PM EDT
|Bid||1.4800 x 2200|
|Ask||1.5200 x 4000|
|Day's Range||1.4401 - 1.5000|
|52 Week Range||0.3820 - 3.5780|
|Beta (3Y Monthly)||5.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.63|
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
Trevena, Inc. (NASDAQ:TRVN) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share...
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to.
The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi.
As we've seen over the last few years, tech companies have invested resources in artificial intelligence, automation, quantum computing, and augmented reality to pioneer technologies to drive society into the future. ParcelPal Technology Inc (PTNYF) (PKG), Trevena Inc (TRVN), China Finance Online Co. Limited (JRJC), and Luna Innovations Incorporated (LUNA) represent 4 tech stocks on the rise on Monday. The Company is focused on improving the lives of their customers through their on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.
CHESTERBROOK, Pa., March 04, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...
HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...
CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
The Chester County biopharmaceutical expects to initiate a new study for its experimental pain medicine, requested by the FDA, during the first half of this year.